Tsiogkas Sotirios G, Perricone Carlo, Bogdanos Dimitrios P
Department of Rheumatology and Clinical Immunology, Faculty of Medicine, University of Thessaly, University General Hospital of Larissa, Greece.
Section of Rheumatology, Department of Medicine and Surgery, University of Perugia, Italy.
Mediterr J Rheumatol. 2024 Mar 30;35(Suppl 1):20-26. doi: 10.31138/mjr.171223.tej. eCollection 2024 Mar.
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin of patients with psoriasis. In this review we aimed to summarise the available evidence regarding the effect of Janus kinase inhibitors (JAKi) on patient-reported outcomes (PROs) when used for the management of PsA.
We utilised a narrative review approach as we searched the available literature for articles to be included in our study.
JAKi have been found to be effective in inducing better PRO responses compared to placebo. These findings have been consistent across various patient populations, including those with active PsA, those with an inadequate response to conventional therapies, and those with comorbidities. The evidence supporting the benefits of JAKi on PROs in PsA is compelling, demonstrating consistent improvements in pain, physical function, fatigue, and quality of life.
Numerous studies have demonstrated the the efficacy of JAKi in improving PROs in patients with PsA.
银屑病关节炎（PsA）是一种慢性炎症性疾病，会影响银屑病患者的关节和皮肤。在本综述中，我们旨在总结关于Janus激酶抑制剂（JAKi）用于治疗PsA时对患者报告结局（PROs）影响的现有证据。
我们采用叙述性综述方法，在现有文献中搜索纳入本研究的文章。
与安慰剂相比，已发现JAKi在诱导更好的PRO反应方面有效。这些发现适用于各种患者群体，包括活动性PsA患者、对传统疗法反应不足的患者以及合并症患者。支持JAKi对PsA患者PROs有益的证据令人信服，表明在疼痛、身体功能、疲劳和生活质量方面持续改善。
大量研究已证明JAKi在改善PsA患者PROs方面的疗效。
